Prediction of Surgical Resectability After FOLFIRINOX Chemotherapy for Borderline Resectable and Locally Advanced Pancreatic Cancer: the Role of Diffusion Weighted Magnetic Resonance Imaging, Radiomics and Liquid Biopsy (PeRFormanCe Trial)

NARecruitingINTERVENTIONAL
Enrollment

45

Participants

Timeline

Start Date

December 12, 2022

Primary Completion Date

March 31, 2026

Study Completion Date

March 31, 2028

Conditions
Pancreatic Cancer
Interventions
DIAGNOSTIC_TEST

Imaging analysis of CT-scan and MRI with radiomics and genetic analysis of peripheral blood samples and questionnaires.

"* The images from CT scans and MRI with DWI will be processed using specialized software to determine the direction of diffusion tensors. This will indicate the diffusion direction using color coding (red, green, and blue for the x, y, and z components of the vector) and the intensity using anisotropy (brightness of voxels). Further analysis will be performed using fiber tracking, which provides a clear representation of the functional connectivity of adjacent tissues.~* Genetic profiling of liquid biopsies: Multi-omics profiling of liquid biopsies (blood samples) will be conducted, followed by cell phenotyping, longitudinal analysis of driver mutations and epigenetic changes in cfDNA, and genotyping of germline variations.~* Questionnaires for patient-reported outcomes and health economic analysis:~EQ-5D-5L PAN 26 HADS"

Trial Locations (8)

9000

RECRUITING

Ghent University Hospital, Ghent

RECRUITING

AZ Jan Palfijn Ghent, Ghent

RECRUITING

AZ Sint Lucs Ghent, Ghent

9100

RECRUITING

AZ Vitaz Sint Niklaas - Lokeren, Sint-Niklaas

9200

RECRUITING

AZ Sint Blasius Dendermonde, Dendermonde

9700

RECRUITING

AZ Oudenaarde, Oudenaarde

9900

RECRUITING

AZ Alma Eeklo, Eeklo

4535 PA

RECRUITING

ZorgSaam ZH DeHonte Terneuzen, Terneuzen

All Listed Sponsors
lead

University Hospital, Ghent

OTHER